Name : Ms. MOHSEENA Patient UID.
: 9659066
Age/Gender : 27 Yrs/Female Visit No. : 0816225081700001
Referred Client : LDPLUP238-JEEVAN CARE PATH LAB Collected on : 16-Aug-2025 10:00AM
Referred By : NA Received on : 17-Aug-2025 07:39AM
Doctor Name : Reported on : 19-Aug-2025 06:47PM
Sample Type : Serum & EDTA Plasma - 18616402
MOLECULAR BIOLOGY
Test Name Results Unit Bio. Ref. Interval
HEPATITIS B VIRUS - VIRAL LOAD (QUANTITATIVE) : REAL TIME PCR
HEPATITIS B VIRAL DNA TARGET NOT DETECTED
Methodology: Real Time Multiplex PCR
RESULTS INTERPRETATION
RESULT in IU/mL REMARKS
Target not detected Likely below the lower limit of linear range of the assay
HBV DNA detected, but below the lower limit of linear range of the assay These results should be
<20
interpreted with caution
>=20 to 1 x109 HBV DNA detected within the linear range of the assay
>1 x 109 HBV DNA detected above the linear range of the assay
COMMENTS
1.Linear reporting range of the assay is 20 - 1 x 10^9 IU/mL
2. Conversion factor: 1 IU/mL = 5.82 copies /mL
3.Test conducted on Serum / Plasma
4.This test is not intended for use as a screening test for the presence of HBV in blood or blood products or as a diagnostic test to confirm the presence of HBV infection
5.HBV genotyping and Drug resistance is recommended in positive cases if value is >2000 IU/mL.
6.A "DETECTED" result will be reported with quantification in IU/ml. It indicates the degree if active HBV viral replication in the patient.
A "LESS THAN DETECTABLE LIMIT" result indicates that either absence of HBV DNA in patient’s specimen or HBV DNA level is below the lower limit of quantification of this
assay.
CLINICAL RELEVANCE
Hepatitis B Virus (HBV) is a member of Hepa DNA virus family transmitted primarily by body fluids especially serum; sexual transmission and transmission from mother to
baby. Majority of the infected individuals recover completely; about 1-2% have persistent viral replication leading to chronic hepatitis. Frequency of chronic HBV infection is
5-10% in immunocompromised patients and 80% in neonates.
CLINICAL APPLICATION
1.Monitoring response to therapy in chronic HBV infection
2.Predict response to favourable treatment outcome
3.valuable tool when used in conjunction with other serological markers in the management of HBV infection
LIMITATIONS
1.This test can quantitate/detect Hepatitis B Virus DNA over the range 20- 1X10^9 IU/mL. However this does not mean that lower copies or higher copies cannot be
detected. The lower copies can be detected in some cases. This is a limitation of the currently available extraction systems.
2.Patients suffering from chronic HBV infection typically have intermittent viraemia. Samples collected during the non- viraemic phase may test negative despite the presence
of active infection. Hence, in such cases where HBV PCR is negative despite strong clinical suspicion, a repeat sample collected at an interval of two weeks from the initial
sample is strongly recommended to rule out active disease.
3. The result of this test must always be correlated with clinical status and history of the patient and other relevant data and should not be used alone for the interpretation.
4. Although all precautions are taken during molecular genetic tests, the currently available data indicate that the technical error in molecular DNA analysis is approximately
2%. It is important that all clinicians or persons requesting Molecular Diagnostic testing are aware of these data before acting upon the results.
5. The results assume that the sample is provided from this patient only and that all patient information provided is correct.
*** End Of Report ***
Page 1 of 1
